Number of the records: 1  

Novel SAMD9 Mutation in a Patient With Immunodeficiency, Neutropenia, Impaired Anti-CMV Response, and Severe Gastrointestinal Involvement

  1. 1.
    SYSNO ASEP0522736
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleNovel SAMD9 Mutation in a Patient With Immunodeficiency, Neutropenia, Impaired Anti-CMV Response, and Severe Gastrointestinal Involvement
    Author(s) Formankova, R. (CZ)
    Kanderová, V. (CZ)
    Rackova, M. (CZ)
    Svaton, M. (CZ)
    Brdička, Tomáš (UMG-J) RID
    Říha, P. (CZ)
    Keslova, P. (CZ)
    Mejstříková, E. (CZ)
    Žaliová, M. (CZ)
    Freiberger, T. (CZ)
    Grombirikova, H. (CZ)
    Zemanová, Z. (CZ)
    Vlková, M. (CZ)
    Fencl, F. (CZ)
    Copova, I. (CZ)
    Bronsky, J. (CZ)
    Jabandžiev, P. (CZ)
    Sedláček, P. (CZ)
    Šoukalová, J. (CZ)
    Zapletal, O. (CZ)
    Starý, J. (CZ)
    Trka, J. (CZ)
    Kalina, T. (CZ)
    Kramarzova, K.S. (CZ)
    Hlavackova, E. (CZ)
    Litzman, J. (CZ)
    Froňková, E. (CZ)
    Number of authors27
    Article number2194
    Source TitleFrontiers in Immunology. - : Frontiers Media - ISSN 1664-3224
    Roč. 10, September (2019)
    Number of pages8 s.
    Publication formOnline - E
    Languageeng - English
    CountryCH - Switzerland
    Keywordssamd9 ; mirage ; immunodeficiency ; neutropenia ; cytomegalovirus infection ; dysphagia ; hematopoietic stem cell transplantation ; gastrointestinal disorder
    Subject RIVEB - Genetics ; Molecular Biology
    OECD categoryImmunology
    Method of publishingOpen access
    Institutional supportUMG-J - RVO:68378050
    UT WOS000486387300001
    DOI10.3389/fimmu.2019.02194
    AnnotationMutations in the Sterile alpha motif domain containing 9 (SAMD9) gene have been described in patients with severe multisystem disorder, MIRAGE syndrome, but also in patients with bone marrow (BM) failure in the absence of other systemic symptoms. The role of hematopoietic stem cell transplantation (HSCT) in the management of the disease is still unclear. Here, we present a patient with a novel mutation in SAMD9 (c.2471 G >A, p.R824Q), manifesting with prominent gastrointestinal tract involvement and immunodeficiency, but without any sign of adrenal insufficiency typical for MIRAGE syndrome. He suffered from severe CMV (cytomegalovirus) infection at 3 months of age, with a delayed development of T lymphocyte functional response against CMV, profound T cell activation, significantly reduced B lymphocyte counts and impaired lymphocyte proliferative response. Cultured T cells displayed slightly lower calcium flux and decreased survival. At the age of 6 months, he developed severe neutropenia requiring G-CSF administration, and despite only mild morphological and immunophenotypical disturbances in the BM, 78% of the BM cells showed monosomy 7 at the age of 18 months. Surprisingly, T cell proliferation after CD3 stimulation and apoptosis of the cells normalized during the follow-up, possibly reflecting the gradual development of monosomy 7. Among other prominent symptoms, he had difficulty swallowing, requiring percutaneous endoscopic gastrostomy (PEG), frequent gastrointestinal infections, and perianal erosions. He suffered from repeated infections and periodic recurring fevers with the elevation of inflammatory markers. At 26 months Frontiers of age, he underwent HSCT that significantly improved hematological and immunological laboratory parameters. Nevertheless, he continued to suffer from other conditions, and subsequently, he died at day 440 post-transplant due to sepsis. Pathogenicity of this novel SAMD9 mutation was confirmed experimentally. Expression of mutant SAMD9 caused a significant decrease in proliferation and increase in cell death of the transfected cells.
    WorkplaceInstitute of Molecular Genetics
    ContactNikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217
    Year of Publishing2020
    Electronic addresshttps://www.frontiersin.org/articles/10.3389/fimmu.2019.02194/full
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.